Pasi A. Jänne
YOU?
Author Swipe
View article: Trastuzumab Deruxtecan for <i>ERBB2</i> -Mutant Metastatic Non–Small Cell Lung Cancer With or Without Brain Metastases
Trastuzumab Deruxtecan for <i>ERBB2</i> -Mutant Metastatic Non–Small Cell Lung Cancer With or Without Brain Metastases Open
Importance Brain metastases reduce overall survival rates of patients with non–small cell lung cancer (NSCLC); patients with epidermal growth factor receptor 2 ( ERBB2 [formerly HER2 ])–mutant NSCLC are more likely to have baseline brain m…
View article: Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors Open
Purpose: AXL, a receptor tyrosine kinase related to oncogenic processes, is aberrantly expressed in various cancers and associated with treatment resistance. Enapotamab vedotin (EnaV), a novel anti-AXL human IgG1 and monomethyl auristatin …
View article: Supplementary Figure S3 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Figure S3 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry Open
Supplementary Figure S3: Kaplan–Meier curve of overall survival from time of diagnostic testing. Survival curve showing overall survival from the date of the positive test that led to the diagnosis of NUT carcinoma. The y-axis indicates ov…
View article: Supplementary Table S2 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Table S2 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry Open
Supplementary Table S2: Patients who had a NUT IHC test and underwent DNA, ctDNA, or RNA fusion testing specifically assaying for NUTM1 fusions.
View article: Supplementary Table S3 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Table S3 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry Open
Supplementary Table S3: Co-occurring mutations found in DNA-based NGS with clinical relevance in NUT carcinoma.
View article: Supplementary Figure S5 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Figure S5 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry Open
Supplementary Figure S5: Gene Ontology enrichment analysis of co-occurring alterations in NC. Bar plots displaying the top enriched Gene Ontology (GO) terms generated using the SRplot online platform. GO categories include (A) Biological P…
View article: Supplementary Figure S4 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Figure S4 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry Open
Supplementary Figure S4: Tumor mutation burden and PD-L1 expression among cases with DNA NGS testing. (A) Box-and-whisker plot showing tumor mutation burden (B) Bar chart showing the distribution of PD-L1 expression levels, stratified by t…
View article: Supplementary Figure S6 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Figure S6 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry Open
Supplementary Figure S6: Schematic of an example gene fusion event leading to NUT carcinoma pathogenesis. Diagram illustrating the fusion of the BRD4 and NUTM1 genes following chromosomal rearrangement. The NUTM1 fusion protein drives onco…
View article: Supplementary Figure S2 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Figure S2 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry Open
Supplementary Figure S2: Histopathological diagnosis in patients with NC who only had a NUT IHC test. Donut chart displaying the distribution of diagnoses among patients diagnosed with NUT carcinoma based only on IHC. Diagnostic categories…
View article: Supplementary Figure S1 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Figure S1 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry Open
Supplementary Figure S1: Flowchart of patient selection and cohort assignment. Flow diagram illustrating the inclusion and exclusion of patients from the NUT carcinoma registry. Boxes show the number of patients included/excluded and how p…
View article: Data from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Data from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry Open
Purpose:NUT carcinoma (NC) is an underdiagnosed, poorly differentiated squamous cell cancer with a median survival of 6.7 months. Defined by NUTM1 fusions, NC enhances oncogene transcription, including MYC. We investigated the ability of s…
View article: Supplementary Table S1 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Table S1 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry Open
Supplementary Table S1: Unique DNA, RNA, and ctDNA assays used in this study.
View article: Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors Open
Antibody-based therapies have revolutionized cancer treatment but have several limitations. These include downregulation of the target antigen, mutation of the target epitope, and, in the case of antibody–drug conjugates (ADC), resistance …
View article: First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC
First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC Open
Purpose: First-line treatment options for MET exon 14 skipping–mutant metastatic non–small cell lung cancer vary because of differences in drug approvals and clinical experience. This study investigates factors influencing outcomes with fi…
View article: Eradicating Drug-tolerant Persister Cells in <i>EGFR-</i> Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
Eradicating Drug-tolerant Persister Cells in <i>EGFR-</i> Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy Open
EGFR tyrosine kinase inhibitors have dramatically improved outcomes for patients with EGFR-mutated non–small cell lung cancer (NSCLC), but relapse frequently occurs because of drug-tolerant persister (DTP) cells that can evolve and develop…
View article: Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry Open
Purpose: NUT carcinoma (NC) is an underdiagnosed, poorly differentiated squamous cell cancer with a median survival of 6.7 months. Defined by NUTM1 fusions, NC enhances oncogene transcription, including MYC. We investigated the ability of …
View article: Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy Open
PURPOSE Patritumab deruxtecan (HER3-DXd; MK-1022) is an investigational HER3-directed antibody-drug conjugate composed of a human immunoglobulin G1 monoclonal antibody to HER3 (patritumab) covalently linked via a stable tetrapeptide-based …
View article: Supplementary Table S4 from Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples
Supplementary Table S4 from Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples Open
Supplemental Table 4. Summary of Duration of Response (Confirmed) by BICR Assessment
View article: Supplementary Table S3 from Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples
Supplementary Table S3 from Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples Open
Supplemental Table 3. Summary of Best Overall Response (Confirmed) by BICR Assessment
View article: Data from Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples
Data from Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples Open
Purpose:Next-generation sequencing assays for ctDNA analysis are routinely used in the care of patients with advanced non–small cell lung cancer. However, variable assay sensitivities in detection of fusions have been reported. Here, we re…
View article: Supplementary Table S6 from Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples
Supplementary Table S6 from Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples Open
Supplemental Table 6. Summary of low pass whole genome purity (RES Bio), ctDNA tumor fractions (FMI), and maximum VAF (GH) results
View article: Supplementary Table S5 from Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples
Supplementary Table S5 from Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples Open
Supplemental Table 5. Summary of Progression-Free Survival by BICR Assessment
View article: Supplementary Table S2 from Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples
Supplementary Table S2 from Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples Open
Supplemental Table 2. Patient Demographic for the study and ITT cohort
View article: Supplementary Table S1 from Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples
Supplementary Table S1 from Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples Open
Supplemental Table 1: RET summary for Tumor, ctDx-First , Guardant360, and F1LCDx
View article: Data from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements
Data from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements Open
Oncogenic translocations involving the MET gene have been reported in several cancer types, but detailed clinicogenomic characterization of these cancers is not well defined. In addition, prospective clinical trials evaluating the antitumo…
View article: Supplementary Figures S1-S9 from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements
Supplementary Figures S1-S9 from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements Open
Supplementary Figure 1. Identification of MET rearrangement cases in the DFCI and GRCC cohorts. Supplementary Figure 2. Genomic features of MET rearrangements. Supplementary Figure 3. Oncoprint of likely oncogenic MET rearrangements and of…
View article: Supplementary Tables S1-S6 from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements
Supplementary Tables S1-S6 from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements Open
Supplementary Table 1. Clinical characteristics of patients with MET rearrangement-positive tumors in the DFCI/GRCC clinicopathologic cohort. Supplementary Table 2. Clinical characteristics of patients with MET fusion-positive tumors in th…